Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated whole virion H5N1 vaccine + aluminium hydroxide
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **inactivated whole virion H5N1 vaccine + aluminium hydroxide** is a monovalent vaccine designed for pandemic preparedness against the H5N1 strain of avian influenza. Unlike split-virion or subunit vaccines, this formulation utilizes the entire inactivated virus particle, which preserves the full array of viral antigens and has been shown to be more immunogenic in populations that are immunologically naive to the H5 strain. The addition of **aluminium hydroxide** (alum) as an adjuvant enhances the immune response by creating a depot effect at the injection site and stimulating the recruitment of antigen-presenting cells. This specific formulation has been developed and stockpiled by several manufacturers, most notably **Sinovac** (under the brand name Panflu) in China and a consortium of manufacturers in Japan, to provide a rapid response capability in the event of an H5N1 influenza pandemic.
- Brand names
- Panflu
- Other names
- H5N1 whole virion vaccineH-5N1 whole virion vaccineH 5N1 whole virion vaccineinactivated H5N1 vaccine with alumVero cell-derived inactivated whole virion H5N1 vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on inactivated whole virion H5N1 vaccine + aluminium hydroxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated whole virion H5N1 vaccine + aluminium hydroxide.